Natalizumab, Efalizumab, and Progressive Multifocal Leukoencephalopathy (PML)

    Basic Details
    Date Posted
    Thursday, January 10, 2013
    Medical Product
    Health Outcome(s)
    progressive multifocal leukoencephalopathy (PML)

    Modular program-based one-time assessment of the risk of progressive multifocal leukoencephalopathy (PML) associated with use of natalizumab and efalizumab in the Mini-Sentinel Distributed Database. Modular programs are adaptable standardized programs. Queries were executed in May 2012.

    If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to

    The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

    Additional Details
    FDA Center
    Time Period
    2003 - 2011
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)